References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/ms2022-026

medsovet-7561

Research Article

ЗАБОЛЕВАНИЯ БИЛИАРНОЙ СИСТЕМЫ И ПЕЧЕНИ

DISEASES OF THE BILIARY SYSTEM AND LIVER

Полиморфизмы генов HSD17B13, GCKR, HFE и CP как факторы развития неалкогольной жировой болезни печени и сопутствующих ее заболеваний

Polymorphisms of HSD17B13, GCKR, HFE, and CP as factors of the development of non-alcoholic fatty liver disease and comorbid diseases

https://orcid.org/0000-0003-3992-9207

Смирнова

О. В.

Smirnova

O. V.

Смирнова Ольга Валентиновна, д.м.н., профессор, заведующая лабораторией клинической патофизиологии, главный научный сотрудник; профессор

660022, Красноярск, ул. Партизана Железняка, д. 3 «Г»;660041, Красноярск, пр. Свободный, д. 79

Olga V. Smirnova, Dr. Sci. (Med.), Professor, Head of Laboratory of Clinical Pathophysiology; Professor

3G, Partizan Zheleznyak St., Krasnoyarsk, 660022;79, Svobodnyy Ave, Krasnoyarsk, 660041

ovsmirnova71@mail.ru

https://orcid.org/0000-0003-1295-9262

Лагутинская

Д. В.

Lagutinskaya

D. V.

Лагутинская Дарья Владимировна, младший научный сотрудник; аспирант

660022, Красноярск, ул. Партизана Железняка, д. 3 «Г»;660041, Красноярск, пр. Свободный, д. 79

Darya V. Lagutinskaya, Juniour Research Associate; Postgraduate Student

3G, Partizan Zheleznyak St., Krasnoyarsk, 660022;79, Svobodnyy Ave, Krasnoyarsk, 660041

dlagut1210@gmail.com

Научно-исследовательский институт медицинских проблем Севера; Сибирский федеральный университетРоссияScientific Research Institute of medical problems of the North; Siberian Federal UniversityRussian Federation

2023

25052023

08119125

2023

Смирнова О.В., Лагутинская Д.В.

Smirnova O.V., Lagutinskaya D.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/7561

В настоящее время неалкогольная жировая болезнь печени (НАЖБП) является одним из самых распространенных хронических заболеваний печени. Данное состояние рассматривается как печеночная манифестация метаболического синдрома, который связан с избыточным весом и нарушением обмена глюкозы и жиров. Несмотря на очевидную роль образа жизни в появлении этой болезни, все больше высказывается предположений о том, что нарушения метаболизма жиров и углеводов имеют под собой генетическую основу, которая и определяет склонность к развитию НАЖБП. Показано, что мутантные полиморфизмы генов HSD17B13, GCKR, HFE и CP оказывают влияние на течение НАЖБП, однако эти эффекты требуют дополнительного изучения. Поэтому целью данной работы явились анализ и систематизация имеющихся данных об их влиянии на состояние пациентов с НАЖБП из преимущественно зарубежных источников за последние 10 лет. В ходе исследования было проанализировано 573 литературных источника, в работе были использованы наиболее важные 64 источника. Мутация гена HSD17B13 связывается с более легким течением НАЖБП, тогда как полиморфизмы гена GCKR, напротив, связаны с более тяжелыми гистологическими проявлениями данного заболевания, например, стеатоз и фиброз. Гены HFE и CP, хоть и не связаны напрямую с обменом макронутриентов, тем не менее, способствуют развитию более тяжелых форм НАЖБП, что может быть связано с развитием воспаления и оксидативного стресса, вызванного избыточным накоплением железа в гепатоцитах.

Currently, non-alcoholic fatty liver disease is one of the most common chronic liver diseases. In recent years, this condition has been considered as a hepatic manifestation of the metabolic syndrome, which is associated with overweight and impaired glucose and fat metabolism. Despite the obvious role of lifestyle in the development of this disease, it is increasingly being suggested that disorders in the metabolism of fats and carbohydrates have a genetic basis, which determines the tendency to develop NAFLD. Mutant polymorphisms of the HSD17B13, GCKR, HFE, and CP genes have been shown to affect the course of NAFLD, but these effects require further study. Therefore, the aim of this work was to analyze and systematize the available data from foreign articles over the past 10 years. In this study, 573 articles were analyzed, the most important 64 original research works were used here. Mutations in the HSD17B13 gene are associated with a milder course of NAFLD, while GCKR gene polymorphisms, on the contrary, are associated with more severe histological manifestations of this disease, such as steatosis and fibrosis. The HFE and CP genes, although not directly related to macronutrient metabolism, nevertheless contribute to the development of more severe forms of NAFLD, which may be associated with the development of inflammation and oxidative stress caused by excessive accumulation of iron in hepatocytes.

неалкогольная жировая болезнь печениHSD17B13GCKRHFECPобмен железа

nonalcoholic fatty liver diseaseHSD17B13GCKRHFECPiron metabolism

Работа написана в рамках госзадания № 0287-2021-0005 «Исследование молекулярно-генетических и регуляторно-метаболических механизмов функциональной активности клеток иммунной системы в норме и при иммунопатологических состояниях».

The work was written within the framework of the state task No. 0287-2021-0005 “Study of moleculargenetic and regulatory-metabolic mechanisms of the functional activity of cells of the immune system in normal and immunopathological conditions”.

References1

Vernon G., Baranova A., Younossi Z. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285. https://doi.org/10.1111/j.1365-2036.2011.04724.x.

Marchesini G., Mazzotti A. NAFLD incidence and remission: Only a matter of weight gain and weight loss? J Hepatol. 2015;62(1):15–17. https://doi.org/10.1016/j.jhep.2014.10.023.

Kitamoto T., Kitamoto A., Yoneda M., Hyogo H., Ochi H., Nakamura T. et. al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013;132(7):783–792. https://doi.org/10.1007/s00439-013-1294-3.

Speliotes E., Yerges-Armstrong L., Wu J., Hernaez R., Kim L., Palmer C. et al. Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits. PLoS Genet. 2011;7(3):e1001324. https://doi.org/10.1371/journal.pgen.1001324.

Kozlitina J., Smagris E., Stender S., Nordestgaard B., Zhou H., Tybjaerg-Hansen A. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver diseas. Nat Genet. 2014;46(4):352–356. https://doi.org/10.1038/ng.2901.

Kozlitina J., Smagris E., Stender S., Nordestgaard B., Zhou H., TybjaergHansen A. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver diseas. Nat Genet. 2014;46(4):352–356. https://doi.org/10.1038/ng.2901.

Basyte-Bacevice V., Skieceviciene J., Valentiene I., Sumskiene J., Petrenkiene V., Kondrackiene J. et al. TM6SF2 and MBOAT7 Gene Variants in Liver Fibrosis and Cirrhosis. Int J Mol Sci. 2019;20(6):1277. https://doi.org/10.3390/ijms20061277.

Krawczyk M., Rau M., Schattenberg J., Bantel H., Pathil A., Demir M. et al. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsybased study. J Lipid Res. 2017;58(1):247–255. https://doi.org/10.1194/jlr.P067454.

Chambers J., Zhang W., Sehmi J., Li X., Wass M., Van der Harst P. et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet. 2011;43(11):1131–1138. https://doi.org/10.1038/ng.970.

Abul-Husn N., Cheng X., Li A., Xin Y. Schurmann C., Stevis P. et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378(12):1096–1106. https://doi.org/10.1056/NEJMoa1712191.

Abul-Husn N., Cheng X., Li A., Xin Y. Schurmann C., Stevis P. et al. A ProteinTruncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med. 2018;378(12):1096–1106. https://doi.org/10.1056/NEJMoa1712191.

Nelson J., Bhattacharya R., Lindor K., Chalasani N., Raaka S., Heathcote E. et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology. 2007;46(3):723–729. https://doi.org/10.1002/hep.21742.

Ma Y., Karki S., Brown P., Lin D.D., Podszun M.C., Zhou W. et al. Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity. J Lipid Res. 2020;61(11):1400–1409. https://doi.org/10.1194/jlr.RA120000907.

Ma Y., Belyaeva O., Brown P., Fujita K., Valles K., Karki S. et al. HSD17B13 is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non-Alcoholic Fatty Liver Disease. Hepatology. 2019;69(4):1504–1519. https://doi.org/10.1002/hep.30350.

Ma Y., Brown P., Lin D., Ma J., Feng D., Belyaeva O. et al. 17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury. Hepatology. 2021;73(5):1701–1716. https://doi.org/10.1002/hep.31517.

Pirola C., Garaycoechea M., Flichman D., Arrese M., Martino J., Gazzi C. et al. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. J Lipid Res. 2019;60(1):176–185. https://doi.org/10.1194/jlr.P089953.

Bellan M., Coletta C., Barbaglia M., Salmi L., Clerici R., Mallela V. et al. Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms. Diabetes Metab J. 2019;43(5):700–710. https://doi.org/10.4093/dmj.2018.0201.

Scheiner B., Stattermayer A., Schwabl P., Bucsics T., Paternostro R., Bauer D. et al. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Liver Int. 2020;40(2):393–404. https://doi.org/10.1111/liv.14304.

Vilar-Gomez E., Pirola C., Sookoian S., Wilson L., Liang T., Chalasani N. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD. Clin Transl Gastroenterol. 2021;12(9):e00400. https://doi.org/10.14309/ctg.0000000000000400.

Luukkonen P., Tukiainen T., Juuti A., Sammalkorpi H., Haridas N., Niemela O. et al. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight. 2020;5(5):e132158. https://doi.org/10.1172/jci.insight.132158.

Ting Y., Kong A., Zain S., Chan W., Tan H., Mohamed Z. et al. Loss-offunction HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. Clin Mol Hepatol. 2021;27(3):486–498. https://doi.org/10.3350/cmh.2020.0162.

Liu W., Eslam M., Zheng K., Ma H., Rios R., Lv M. et al. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol. 2021;9(2):194–202. https://doi.org/10.14218/JCTH.2020.00151.

Jansson-Knodell C., Gawrieh S., McIntyre A., Liang T., Hegele R., Chalasani N. APOB and PNPLA3 Double Heterozygosity in a Father-Son Pair with Advanced Nonalcoholic Fatty Liver Disease. Hepatology. 2020;71(1):383–385. https://doi.org/10.1002/hep.30874.

Kallwitz E., Tayo B., Kuniholm M., Daviglus M., Zeng D., Isasi C., Cotler S. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos. Liver Int. 2020;40(4):889–983. https://doi.org/10.11/11/liv.14387.

Pautsch A., Stadler N., Lohle A., Rist W., Berg A., Glocker L. et al. Crystal Structure of Glucokinase Regulatory Protein. Biochemistry. 2013;52(20):3523–3531. https://doi.org/10.1021/bi4000782.

Choi J., Seo M., Kyeong H., Kim E., Kim H. Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase. Proc Natl Acad Sci. USA. 2013;110(25):10171–10176. https://doi.org/10.1073/pnas.1300457110.

Costanzo A., Belardinilli F., Bailetti D., Sponziello M., D’Erasmo L., Polimeni L. et al. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Sci Rep. 2018;8(1):3702. https://doi.org/10.1038/s41598-018-21939-0.

Xu L., Yin L., Qi Y., Tan X., Gao M., Peng J. 3D disorganization and rearrangement of genome provide insights into pathogenesis of NAFLD by integrated Hi-C, Nanopore, and RNA sequencing. Acta Pharm Sin B. 2021;11(10):3150–3164. https://doi.org/10.1016/j.apsb.2021.03.022.

Kawaguchi T., Shima T., Mizuno M., Mitsumoto Y., Umemura A., Kanbara Y. et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS ONE. 2018;13(1):e0185490. https://doi.org/10.1371/journal.pone.0185490.

Petta S., Miele L., Bugianesi E., Camma C., Rosso C., Boccia S. et al. Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE. 2014;9(2):e87523. https://doi.org/10.1371/journal.pone.0087523.

Pirola C., Flichman D., Dopazo H., Gianotti T., Martino J., Rohr C. et al. A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis. Hepatol Commun. 2018;2(9):1030–1036. https://doi.org/10.1002/hep4.1235.

Petit J., Masson D., Guiu B., Rollot F., Duvillard L., Bouillet B. et al. GCKR polymorphism influences liver fat content in patients with type 2 diabetes. Acta Diabetol. 2016;53(2):237–242. https://doi.org/10.1007/s00592-015-0766-4.

Lin Y., Chang P., Chang M., Ni Y. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr. 2014;99(4):869–874. https://doi.org/10.3945/ajcn.113.079749.

Rees M., Raimondo A., Wang J., Ban M., Davis M., Barret A. et al. Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Hum Mol Genet. 2014;23(20):5570–5578. https://doi.org/10.1093/hmg/ddu269.

Kitamoto A., Kitamoto T., Nakamura T., Ogawa Y., Yoneda M., Hyogo H. et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr J. 2014;61(7):683–689. https://doi.org/10.1507/endocrj.ej14-0052.

Yang Z., Wen J., Tao X., Lu B., Du Y., Wang M. et al. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep. 2011;38(2):1145–1150. https://doi.org/10.1007/s11033-010-0212-1.

Kaliora A., Kalafati I., Gioxari A., Diolintzi A., Kokkinos A., Dedoussis G. A modified response of NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326. Eur J Nutr. 2018;57(6):2227–2235. https://doi.org/10.1007/s00394-017-1499-7.

Costanzo A., Pacifico L., Chiesa C., Perla F., Ceci F., Angeloni A. et al. Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity. Pediatr Res. 2019;85(5):671–677. https://doi.org/10.1038/s41390-019-0303-1.

Hudert C., Selinski S., Rudolph B., Blaker H., Loddenkemper C., Thielhorn R. et al. Genetic determinants of steatosis and fibrosis progression in paediatric non‐alcoholic fatty liver disease. Liver Int. 2019;39(3):540–556. https://doi.org/10.1111/liv.14006.

Cid-Soto M., Martinez-Hernandez A., Garcia-Ortiz H., Cordova E., Barajas-Olmos F., Centeno-Cruz F. et al. Gene variants in AKT1, GCKR and SOCS3 are differentially associated with metabolic traits in Mexican Amerindians and Mestizos. Gene. 2018;679:160–171. https://doi.org/10.1016/j.gene.2018.08.076.

Fallo F., Pozza A., Sonino N., Lupia M., Tona F., Federspil G. et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis. 2009;19(9)646–653. https://doi.org/10.1016/j.numecd.2008.12.007.

Wu S., Wu F., Ding Y., Hou J., Bi J., Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386. https://doi.org/10.1038/srep33386.

Sung K., Wild S., Byrne C. Resolution of Fatty Liver and Risk of Incident Diabetes. Clin Endocrinol Metab. 2013;98(9):3637–3643. https://doi.org/10.1210/jc.2013-1519.

Sun D., Jin Y., Wang T., Zheng K., Rios R., Zhang H. et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433. https://doi.org/10.1016/j.metabol.2020.154433.

Paik J., Golbali P., Younoszai Z., Mishra A., Trimble G., Younossi Z. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int. 2019;39(2):342–352. https://doi.org/10.1111/liv.13992.

Sun D., Wang T., Zheng K., Zhang H., Wang X., Targher G. et al. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2021;31(6):1822–1831. https://doi.org/10.1016/j.numecd.2021.02.018.

Sessa A., Umano G., Cirilo G., Passaro A., Verde V., Cozzolino D. et al. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of HSD17B13 variant. World J Gastroenterol. 2020;26(36):5474–5483. https://doi.org/10.3748/wjg.v26.i36.5474.

Dekkers I., Vries A., Smit R., Rosendaal F., Rabelink T., Lamb H., de Mutsert R. The Separate Contributions of Visceral Fat and Liver Fat to Chronic Kidney Disease-Related Renal Outcomes. J Ren Nutr. 2020;30(4):286–295. https://doi.org/10.1053/j.jrn.2019.09.002.

Costanzo A., Pacifico L., D’Erasmo L., Polito L., Di Martino M., Perla F. et al. Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. Int J Mol Sci. 2019;20(18):4444. https://doi.org/10.3390/ijms20184444.

Sun D., Zheng K., Xu G., Ma H., Zhang H., Pan X. et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int. 2020;40(1):107–119. https://doi.org/10.1111/liv.14251.

Musso G., Cassader M., Gambino R. PNPLA3 rs738409 and TM6SF2 rs58542926 Gene Variants Affect Renal Disease and Function in Nonalcoholic Fatty Liver Disease. Hepatology. 2015;62(2):658–659. https://doi.org/10.1002/hep.27643.

Ryan E., Ryan J., Russell J., Coughlan B., Tjalsma H., Swinkels D. et. al. Correlates of Hepcidin and NTBI according to HFE Status in Patients Referred to a Liver Centre. Acta Haematol. 2015;133(2):155–161. https://doi.org/10.1159/000363490.

Powell E., Ali A., Clouston A., Dixon J., Lincoln D., Purdie D. et al. Steatosis Is a Cofactor in Liver Injury in Hemochromatosis. Gastroenterology. 2006;129(6):1937–1943. https://doi.org/10.1053/j.gastro.2005.09.015.

Walsh A., Dixon J., Ramm G., Hewett D., Lincoln D., Anderson G. et al. The Clinical Relevance of Compound Heterozygosity for the C282Y and H63D Substitutions in Hemochromatosis. Clin Gastroenterol Hepatol. 2006;4(11):1403–1410. https://doi.org/10.1016/j.cgh.2006.07.009.

Lebron J., Bennett M., Vaughn D., Chirino A., Snow P., Minter G. et al. Crystal Structure of the Hemochromatosis Protein HFE and Characterization of Its Interaction with Transferrin Receptor. Cell. 1998;93(1):111–123. https://doi.org/10.1016/S0092-8674(00)81151-4.

Traeger L., Schnittker J., Dogan D., Oguama D., Kuhlmann T., Muckenthaler M. et al. HFE and ALK3 act in the same signaling pathway. Free Radic Biol Med. 2020;160:501–505. https://doi.org/10.1016/j.freeradbiomed.2020.08.023.

Nelson J., Brunt E., Kowdley K. Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology. 2012;56(5):1730–1740. https://doi.org/10.1002/hep.25856.

Tan T., Crawford D., Jaskowski L., Murphy T., Heritage M., Subramaniam N. et al. Altered lipid metabolism in Hfe-knockout mice promotes severe NAFLD and early fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G865–G876. https://doi.org/10.1152/ajpgi.00150.2011.

Wagner J., Fillebeen C., Haliotis T., Charlebois E., Katsarou A., Mui J. et. al. Mouse models of hereditary hemochromatosis do not develop early liver fibrosis in response to a high fat diet. PLoS ONE. 2019;14(8):e0221455. https://doi.org/10.1371/journal.pone.0221455.

Britton L., Jaskowski L., Bridle K., Santrampurwala N., Reiling J., Musgrave N. et al. Heterozygous Hfe gene deletion leads to impaired glucose homeostasis, but not liver injury in mice fed a high-calorie diet. Physiol Rep. 2016;4(12) :e12837. https://doi.org/10.14814/phy2.12837.

Кривошеев А.Б., Максимов В.Н., Воевода М.И, Куимов A.Д., Кондратова М.А., Тугулева Т.А. и др. Аллели С282Y и Н63D гена HFE, инсулинорезистентность и предрасположенность к нарушению порфиринового обмена при неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2015;(3):39–44.. Режим доступа: https://cyberleninka.ru/article/n/alleli-s282y-i-n63d-gena-hfeinsulinorezistentnost-i-predraspolozhennost-k-narusheniyuporfirinovogo-obmena-pri-nealkogolnoy-zhirovoy/viewer.

Krivosheev A.B., Maximov V.N., Voevoda M.I., Kuimov A.D., Kondratova M.A. Tuguleva T.A. et. al. Alleles С282Y and Н63D HFE gene, insulin resistance and susceptibility to disturbance of porphyrin metabolism in nonalcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2015;(3):39–44. (In Russ.) Available at: https://cyberleninka.ru/article/n/alleli-s282y-i-n63d-gena-hfe-insulinorezistentnost-i-predraspolozhennostk-narusheniyu-porfirinovogo-obmena-pri-nealkogolnoy-zhirovoy/viewer.

Ye Q., Qian B., Yin W., Wang F., Han T. Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non Alcoholic Fatty Liver Disease, Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. PLoS ONE. 2016;11(9):e0163423. https://doi.org/10.1371/journal.pone.0163423.

Corridani E., Buzzetti E., Dongiovanni P., Scarlini S., Caleffi A., Pelusi S. et. al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol. 2021;75(3):506–513. https://doi.org/10.1016/j.jhep.2021.03.014.

Bento I., Peixoto C., Zaitsev V., Lindley P. Ceruloplasmin revisited: structural and functional roles of various metal cation-binding sites. Acta Crystallogr D Biol Crystallogr. 2007;D63:240–248. https://doi.org/10.1107/S090744490604947X.

Nobili V., Siotto M., Bedogni G., Rava L., Pietrobattista A., Panera N. et al. Levels of Serum Ceruloplasmin Associate With Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2013;56(4):370–375. https://doi.org/10.1097/MPG.0b013e31827aced41.

The authors declare that there are no conflicts of interest present.